Completed

Enhanced Schizophrenia Treatment with Approved Drug Combination

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Mental Disorders

+ Schizophrenia

+ Schizophrenia Spectrum and Other Psychotic Disorders

From 18 to 55 Years
+9 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 1 & 2
Interventional
See protocol details

Summary

Principal SponsorEli Lilly and Company
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

This study focuses on improving the treatment of Schizophrenia. It aims to help patients who are currently using one of the following medications: Abilify, Risperdal, Seroquel, or Zyprexa. The goal is to find a better way to manage symptoms and enhance the quality of life for these individuals. This research is important because it could lead to more effective care for people living with Schizophrenia. The study involves testing a combination of two drugs that are already approved for use. Participants will continue taking their current medication and add the new drug to their treatment plan. The effects of this combination will be closely monitored. The study will measure how well the new combination works in managing symptoms and improving daily functioning. As with any study, there may be potential risks and benefits, which will be fully explained to participants before they decide to take part.

Official TitleA Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
NCT00089869
Principal SponsorEli Lilly and Company
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 55 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Mental DisordersSchizophreniaSchizophrenia Spectrum and Other Psychotic Disorders

Criteria

5 inclusion criteria required to participate
Must have been stable on a dose of Abilify, Risperdal, Seroquel, or Zyprexa for the past 8 weeks

Women of childbearing potential must be using a medically accepted means of contraception

Must be able to swallow capsules

Must have a clinical diagnosis of Schizophrenia

Show More Criteria

4 exclusion criteria prevent from participating
Has serious health problems other than Schizophrenia

Takes an antidepressant for depression

Takes insulin for diabetes

Have a history of alcohol or drug dependence (except for nicotine and caffeine) within the past 6 months

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 20 locations

Suspended

"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."

Cerritos, United StatesOpen "For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician." in Google Maps
Suspended

"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician.

Chula Vista, United States
Suspended

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.

Garden Grove, United States
Suspended

"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."

San Diego, United States
Completed20 Study Centers